Tumor-released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non-small cell lung cancer

Currently, resistance to tyrosine kinase inhibitors, such as gefitinib, has become one major obstacle for improving the clinical outcome of patients with metastatic and advanced-stage non-small cell lung cancer (NSCLC). While cell behavior can be modulated by long non-coding RNAs (lncRNAs), the cont...

Descripción completa

Detalles Bibliográficos
Autores principales: Lei, Yi, Guo, Wang, Chen, Bowang, Chen, Lu, Gong, Jiaxin, Li, Weimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196604/
https://www.ncbi.nlm.nih.gov/pubmed/30542738
http://dx.doi.org/10.3892/or.2018.6762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196604/
https://www.ncbi.nlm.nih.gov/pubmed/30542738
http://dx.doi.org/10.3892/or.2018.6762

Ejemplares similares